Hansoh Pharmaceutical Group Co (HKSE:03692) Net Income (Continuing Operations) : HK$3,585 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Hansoh Pharmaceutical Group Co's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was HK$2,175 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$3,585 Mil.

Hansoh Pharmaceutical Group Co Net Income (Continuing Operations) Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Net Income (Continuing Operations) Chart

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

2,845.02

3,045.27

3,321.86

2,885.31

3,584.86

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income (Continuing Operations)	Get a 7-Day Free Trial									1,741.58	1,521.49	1,435.84	1,409.72	2,175.15

Hansoh Pharmaceutical Group Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$3,585 Mil.

Hansoh Pharmaceutical Group Co (HKSE:03692) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Hansoh Pharmaceutical Group Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Net Income (Continuing Operations)

Traded in Other Exchanges

3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines